Corpus Intelligence IC Memo — COLLEGE HOSPITAL INC 2026-04-26 14:30 UTC
IC Memo — COLLEGE HOSPITAL INC
Investment Committee Memorandum | CA | 187 beds | Grade D | EBITDA uplift $5.4M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

COLLEGE HOSPITAL INC

CCN 054055 | LOS ANGELES, CA | 187 beds | April 26, 2026
EBITDA BridgeData Room
D
Investability

1. Target Overview & Investment Thesis

COLLEGE HOSPITAL INC is a 187-bed community hospital in LOS ANGELES, CA with $73.2M in net patient revenue and a -0.7% operating margin. The hospital serves a payer mix of 9.9% Medicare, 0.0% Medicaid, and 90.1% commercial.

Thesis: Undervalued. Our ML models identify $5.4M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -0.7% to 6.6% (+736bps).

Net Revenue HCRIS$73.2M
Current EBITDA COMPUTED$-522K
Operating Margin COMPUTED-0.7%
Occupancy HCRIS92.6%
Revenue / Bed COMPUTED$392K
Net-to-Gross HCRIS48.5%
Distress Probability MLnan%

2. Market Context & Competitive Position

414
CA Hospitals
-4.9%
State Median Margin
220
Comparable Hospitals

CA has 414 Medicare-certified hospitals with a median operating margin of -4.9%. The target's margin of -0.7% places it above the state median. Among 220 size-comparable peers (94-374 beds), the median margin is -4.6%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (94-374), prioritizing same-state peers. 220 hospitals in the comp set.

HospitalStateBedsRevenueMargin
COLLEGE HOSPITAL INC (Target)CA187$73.2M-0.7%
CITY OF HOPE NATIONAL MEDICAL CA217$1.83B-10.7%
HARBOR-UCLA MEDICAL CENTERCA369$1.54B-6.4%
CHILDRENS HOSPITAL OF ORANGE CCA334$1.31B0.7%
KFH - SANTA CLARACA343$1.25B12.5%
KFH - ROSEVILLECA352$1.18B14.2%
KFH - OAKLANDCA365$1.13B-6.3%
KECK HOSPITAL OF USCCA301$1.11B-20.8%
SUTTER ROSEVILLE MEDICAL CENTECA318$1.07B12.1%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $5.4M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$1.5M+210bp18mo
Cost to Collect4.5%2.5%$1.5M+200bp12mo
Denial Rate Reduction12.0%6.5%$1.5M+198bp12mo
A/R Days Reduction5200.0%3800.0%$891K+122bp9mo
Clean Claim Rate88.0%96.0%$47K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$1.5M
Cost to Collect
$1.5M
Denial Rate Reduction
$1.5M
A/R Days Reduction
$891K
Clean Claim Rate
$47K
Total EBITDA Uplift$5.4M
Current EBITDA$-522K
+ RCM Uplift+$5.4M
Pro Forma EBITDA$4.9M
Current Margin-0.7%
Pro Forma Margin6.6%
WC Released (1x)$2.8M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-803K$50.5M0.00x-100.0%
Base (11x exit)10.0x11.0x$-803K$55.3M0.00x-100.0%
Bull Case9.0x11.0x$-722K$72.8M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-722K$79.2M0.00x-100.0%
Bear Case11.0x10.0x$-883K$23.8M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-883K$25.9M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 220 hospitals with 94-374 beds
  • Same-state prioritization (n=221)
  • Comp margins: P25=-17.3% / P50=-4.6% / P75=4.5%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.